Grey Wolf Therapeutics
Oxford, England, United Kingdom · Biotechnology, Health Care, Medical
Grey Wolf Therapeutics is a UK-based drug discovery biotechnology company focused on immuno-oncology and founded by experienced industry professionals Tom McCarthy (Executive Chairman), former President and CEO of Spinifex Pharmaceuticals and Peter Joyce (CEO), formerly of Vertex Pharmaceuticals. Rather than targeting the immune system, Grey Wolf’s approach is to directly alter the tumour cell
Key facts
- Headquarters
- Oxford, England, United Kingdom
- Employees
- 42
- Industries
- Biotechnology, Health Care, Medical
- Status
- Private
- Website
- greywolftherapeutics.com
- Company page
Recent activity at Grey Wolf Therapeutics
- : Greywolf Therapeutics Appoints Darlene Deptula-Hicks as Chief Financial Officer
- : Grey Wolf Therapeutics closes oversubscribed $50 million Series B financing expansion led by ICG Life Sciences team to accelerate and expand first-of-its-kind antigen modulation technology.
- : Pfizer Ventures Co-Leads £40M Funding In Grey Wolf Therapeutics
Grey Wolf Therapeutics funding history
| Date | Round | Amount |
|---|---|---|
| May 2024 | Series B | $50.0M |
| Jan 2023 | Funding Round | $40.0M |
Leadership
- Peter Joyce, CEO and Co-founder
- Lisa Shoesmith, Co-Founder & CSO
- Peter Joyce, Founder
- Darlene Deptula-Hicks, Chief Financial Officer
- Tom Lillie, Chief Medical Officer
- Paul Stainer, Vice President Finance and Business Development
Verified email and direct lines for Grey Wolf Therapeutics’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.
Grey Wolf Therapeutics in the news
- Genomics inks partnership deal with Greywolf to assess gene datasets - Fierce Biotech (May 01, 2026)
- Greywolf Therapeutics Initiates Dosing of First-in-Class Autoimmunity Treatment - The Clinical Trial Vanguard (Aug 14, 2025)
- Grey Wolf Therapeutics Closes Oversubscribed $50 Million Series B Financing Expansion, Led by ICG Life Sciences Team, to Accelerate and Expand First-of-its-Kind Antigen Modulation Technology - PR Newswire (May 23, 2024)
Companies similar to Grey Wolf Therapeutics
- Nanoscope Therapeutics · Biotechnology, Health Care, Medical, Therapeutics
- Specialised Therapeutics · Biotechnology, Health Care, Medical, Therapeutics
- NeuroKaire · Biotechnology, Health Care, Medical, Therapeutics
- Aptose Biosciences · Biotechnology, Health Care, Medical, Therapeutics
- Ascidian Therapeutics · Biotechnology, Health Care, Medical, Therapeutics
About Grey Wolf Therapeutics: questions and answers
What does Grey Wolf Therapeutics do?
Grey Wolf Therapeutics is a UK-based drug discovery biotechnology company focused on immuno-oncology and founded by experienced industry professionals Tom McCarthy (Executive Chairman), former President and CEO of Spinifex Pharmaceuticals and Peter Joyce (CEO), formerly of Vertex Pharmaceuticals. Rather than targeting the immune system, Grey Wolf’s approach is to directly alter the tumour cell
Where is Grey Wolf Therapeutics headquartered?
Grey Wolf Therapeutics is headquartered in Oxford, England, United Kingdom.
How many employees does Grey Wolf Therapeutics have?
Grey Wolf Therapeutics has about 42 employees.
Has Grey Wolf Therapeutics raised funding?
Yes. Fundz has recorded 2 funding events for Grey Wolf Therapeutics. The most recent, Series B of $50.0M, was in May 2024.
Who leads Grey Wolf Therapeutics?
Peter Joyce is a CEO and Co-founder at Grey Wolf Therapeutics.
What is the latest news on Grey Wolf Therapeutics?
On Nov 14, 2024, Greywolf Therapeutics Appoints Darlene Deptula-Hicks as Chief Financial Officer
Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy